SCHEMBL14770508

SCHEMBL14770508

CCOc1ccc(C(C)c2nc3cc(F)ccc3[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
HTT P42858 2/20 0.49
POLB P06746 1/20 0.42
LMNA P02545 4/20 0.39
ALPL P05186 1/20 0.38
ALPI P09923 1/20 0.38
ALPG P10696 1/20 0.38
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
LTC4S Q16873 1/20 0.37
HPGD P15428 4/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ESR2 Q92731 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770571 0.88 KMT2A (0.46) KMT2AMEN1HTTMAPT
SCHEMBL14770598 0.88 KMT2A (0.43) KMT2AMEN1HTTPOLBLMNA
SCHEMBL14770526 0.88 CACNA1C (0.48) KMT2AMEN1HTTPOLBLMNA
SCHEMBL14770491 0.87 KMT2A (0.51) KMT2AMEN1HTTPOLBLMNA
SCHEMBL14770492 0.86 AMY1A (0.41) KMT2AMEN1LMNAALPLALPI
SCHEMBL14770580 0.85 FFAR1 (0.46) KMT2AMEN1HTTLMNAMAPT
SCHEMBL14770531 0.85 CACNA1C (0.40) KMT2AMEN1HTTPOLBLMNA
SCHEMBL14770535 0.84 MEN1 (0.53) KMT2AMEN1HTTPOLBLMNA
SCHEMBL14770501 0.82 MLKL (0.46) KMT2AMEN1HTTLMNAALPL
SCHEMBL14770583 0.82 MEN1 (0.44) KMT2AMEN1HTTLMNAPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A KMT2A 4545/4885MEN1 2676/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.